Anti-amyloid therapies cause ARIA in a subset of patients. We are working on blood-based biomarkers & a whole-blood ex vivo assay to help identify who may benefit and who may be at higher risk, supporting eligibility assessment & monitoring. www.fluidx-ad.eu #WorldAlzMonth #WAM2025

Accessible, low-burden testing matters. FluiDx-AD is working towards validation of saliva and plasma biomarkers as well as automated workflows that fit routine clinics, with documentation to support future regulatory steps. www.fluidx-ad.eu #WorldAlzMonth #WAM2025

“Low-cost & simple” matters when you are waiting for answers. Earlier diagnosis helps people plan, seek support, and know what to expect. We aim to evaluate a three-test approach using saliva & blood biomarkers to support earlier, reliable decisions. #WorldAlzMonth #WAM2025 www.fluidx-ad.eu

Early answers open access to support. FluiDx-AD aims to develop and validate three complementary tests: saliva risk indication, plasma confirmation, and a whole blood ex-vivo assay for ARIA risk to guide therapy decisions. #WorldAlzMonth #WAM2025 #WorldAlzheimersMonth www.fluidx-ad.eu

Early, reliable answers help families plan. FluiDx-AD aims to develop & validate three complementary, minimally invasive tests (saliva-based risk indication, plasma-based confirmatory biomarkers, & an assay for ARIA assessment). www.fluidx-ad.eu #WorldAlzMonth #WAM2025

In FluiDx-AD, we aim to develop & validate a trio of saliva- and blood-based tests to support earlier detection, precise confirmation, and ARIA risk assessment for therapy decisions. More information: www.fluidx-ad.eu #WorldAlzheimersMonth #WAM2025 #WorldAlzMonth

People may have to wait far too long for an Alzheimer’s disease diagnosis. FluiDx-AD aims to shorten diagnostic pathways by developing & standardising fluid-based biomarker tests. linktr.ee/FluiDx_AD #WorldAlzheimersMonth #WAM2025 #WorldAlzMonth

🧠On #WorldBrainDay #WBD2025 we highlight FluiDx-AD, improving early Alzheimer’s diagnosis with saliva & blood-based tests. Led by Oslo University Hospital & Pre Diagnostics, with Alzheimer Europe leading on communication & Public Involvement. 🎥 vimeo.com/1058971988 🔗 linktr.ee/FluiDx_AD

The AI-Mind project builds AI tools to scan brain connectivity and predict dementia risk, giving clinicians earlier insight. Horizon Europe spin-off @fluidx-ad.bsky.social proves the impact. Details in Alzheimer Europe's Dementia in Europe Magazine supplement www.alzheimer-europe.org/sites/defaul...

Survey Study Aims to Assess Germany’s Readiness for Early #Alzheimer Diagnosis Using Biomarkers #ADPD2025 👉 www.neurologylive.com/view/survey-...

A new study shows a saliva test outperforms current blood tests in predicting prostate cancer risk. @fluidx-ad.bsky.social aims to do the same for #Alzheimer’s, with SalivaDx-AD enabling easy at-home risk detection. www.alzheimer-europe.org/our-work/cur... www.theguardian.com/society/2025...

A big thank you to @geriatricarea.bsky.social, who shared our press release about the launch of @fluidx-ad.bsky.social in their news coverage! Link (in Spanish!) below ⏬ www.geriatricarea.com/2025/04/03/e...

The new Alzheimer Europe Dementia in Europe Magazine features an interview with our Scientific Coordinator Erik Christensen, putting a spotlight on the novel test trio to detect peptide biomarkers for enhanced diagnosis & management of #Alzheimer's disease ⤵️ www.alzheimer-europe.org/sites/defaul...

@fluidx-ad.bsky.social is set to improve #Alzheimer’s disease diagnosis with minimally invasive, cost-effective saliva & blood tests. Learn more: alzheimereurope.newsweaver.com/ConferenceAn... www.vimeo.com/1058971988